Leerink Partnrs Upgrades Compass Therapeutics (NASDAQ:CMPX) to Strong-Buy

Leerink Partnrs upgraded shares of Compass Therapeutics (NASDAQ:CMPX - Free Report) from a hold rating to a strong-buy rating in a report published on Tuesday, April 1st,Zacks.com reports. Leerink Partnrs also issued estimates for Compass Therapeutics' Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.66) EPS and FY2026 earnings at ($0.76) EPS.

Other equities research analysts have also issued research reports about the company. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Leerink Partners upgraded Compass Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Guggenheim reissued a "buy" rating and set a $12.00 target price on shares of Compass Therapeutics in a research note on Wednesday, April 2nd. D. Boral Capital restated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Finally, Jefferies Financial Group lifted their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $13.38.

Remove Ads

Compass Therapeutics Price Performance

Shares of CMPX stock traded down $0.02 during trading hours on Tuesday, reaching $1.56. 588,729 shares of the company traded hands, compared to its average volume of 819,640. The firm has a 50-day moving average price of $2.73 and a 200 day moving average price of $2.11. The company has a market cap of $215.03 million, a P/E ratio of -4.18 and a beta of 1.40. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Sell-side analysts predict that Compass Therapeutics will post -0.36 EPS for the current year.

Insider Activity

In other Compass Therapeutics news, insider Jonathan Anderman purchased 20,000 shares of the stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average price of $1.54 per share, with a total value of $30,800.00. Following the acquisition, the insider now owns 21,000 shares in the company, valued at approximately $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 28.50% of the company's stock.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Enavate Sciences GP LLC purchased a new position in shares of Compass Therapeutics in the 4th quarter worth approximately $11,293,000. Tang Capital Management LLC boosted its stake in Compass Therapeutics by 225.4% during the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after buying an additional 4,087,005 shares during the period. MPM Bioimpact LLC increased its position in Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after acquiring an additional 2,926,002 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock valued at $573,000 after acquiring an additional 356,352 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Compass Therapeutics by 512.5% in the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after acquiring an additional 227,864 shares during the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.